160 related articles for article (PubMed ID: 17167792)
21. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.
Yoshikawa Y; Kobayashi K; Oishi S; Fujii N; Furuya T
Bioorg Med Chem Lett; 2012 Mar; 22(6):2146-50. PubMed ID: 22365757
[TBL] [Abstract][Full Text] [Related]
22. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.
Boulais PE; Dulude D; Cabana J; Heveker N; Escher E; Lavigne P; Leduc R
Biochem Pharmacol; 2009 Dec; 78(11):1382-90. PubMed ID: 19631193
[TBL] [Abstract][Full Text] [Related]
23. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
24. A future perspective on the development of chemokine receptor CXCR4 antagonists.
Tamamura H; Tsutsumi H; Nomura W; Tanaka T; Fujii N
Expert Opin Drug Discov; 2008 Oct; 3(10):1155-66. PubMed ID: 23489074
[TBL] [Abstract][Full Text] [Related]
25. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.
Burger JA; Peled A
Leukemia; 2009 Jan; 23(1):43-52. PubMed ID: 18987663
[TBL] [Abstract][Full Text] [Related]
26. Structure-based development of antagonists for chemokine receptor CXCR4.
Zhang C; Hou T; Feng Z; Li Y
Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
[TBL] [Abstract][Full Text] [Related]
27. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
Tamamura H; Omagari A; Hiramatsu K; Gotoh K; Kanamoto T; Xu Y; Kodama E; Matsuoka M; Hattori T; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Jul; 11(14):1897-902. PubMed ID: 11459656
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.
Tamamura H; Hiramatsu K; Ueda S; Wang Z; Kusano S; Terakubo S; Trent JO; Peiper SC; Yamamoto N; Nakashima H; Otaka A; Fujii N
J Med Chem; 2005 Jan; 48(2):380-91. PubMed ID: 15658852
[TBL] [Abstract][Full Text] [Related]
30. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 receptor as a promising target for oncolytic drugs.
Lavrovsky Y; Ivanenkov YA; Balakin KV; Medvedeva DA; Ivachtchenko AV
Mini Rev Med Chem; 2008 Oct; 8(11):1075-87. PubMed ID: 18855724
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres.
Narumi T; Hayashi R; Tomita K; Kobayashi K; Tanahara N; Ohno H; Naito T; Kodama E; Matsuoka M; Oishi S; Fujii N
Org Biomol Chem; 2010 Feb; 8(3):616-21. PubMed ID: 20090978
[TBL] [Abstract][Full Text] [Related]
33. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
[TBL] [Abstract][Full Text] [Related]
34. Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
[TBL] [Abstract][Full Text] [Related]
35. Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.
Di Maro S; Trotta AM; Brancaccio D; Di Leva FS; La Pietra V; Ieranò C; Napolitano M; Portella L; D'Alterio C; Siciliano RA; Sementa D; Tomassi S; Carotenuto A; Novellino E; Scala S; Marinelli L
J Med Chem; 2016 Sep; 59(18):8369-80. PubMed ID: 27571038
[TBL] [Abstract][Full Text] [Related]
36. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
[TBL] [Abstract][Full Text] [Related]
37. Pharmacophore-based small molecule CXCR4 ligands.
Narumi T; Tanaka T; Hashimoto C; Nomura W; Aikawa H; Sohma A; Itotani K; Kawamata M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem Lett; 2012 Jun; 22(12):4169-72. PubMed ID: 22579418
[TBL] [Abstract][Full Text] [Related]
38. Role of CXCR4 in HIV infection and its potential as a therapeutic target.
Murakami T; Yamamoto N
Future Microbiol; 2010 Jul; 5(7):1025-39. PubMed ID: 20632803
[TBL] [Abstract][Full Text] [Related]
39. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.
Choi WT; Yang Y; Xu Y; An J
Curr Top Med Chem; 2014; 14(13):1574-89. PubMed ID: 25159167
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
